Last reviewed · How we verify
Haloperidol and Ramelteon — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Haloperidol and Ramelteon (Haloperidol and Ramelteon) — All India Institute of Medical Sciences, Bhubaneswar.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Haloperidol and Ramelteon TARGET | Haloperidol and Ramelteon | All India Institute of Medical Sciences, Bhubaneswar | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Haloperidol and Ramelteon CI watch — RSS
- Haloperidol and Ramelteon CI watch — Atom
- Haloperidol and Ramelteon CI watch — JSON
- Haloperidol and Ramelteon alone — RSS
Cite this brief
Drug Landscape (2026). Haloperidol and Ramelteon — Competitive Intelligence Brief. https://druglandscape.com/ci/haloperidol-and-ramelteon. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing